Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

A comprehensive evaluation of biomarkers predictive of response to PI3K inhibitors and of resistance mechanisms in head and neck squamous cell carcinoma.

Mazumdar T, Byers LA, Ng PK, Mills GB, Peng S, Diao L, Fan YH, Stemke-Hale K, Heymach JV, Myers JN, Glisson BS, Johnson FM.

Mol Cancer Ther. 2014 Nov;13(11):2738-50. doi: 10.1158/1535-7163.MCT-13-1090. Epub 2014 Sep 5.

2.

The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF.

Watson IR, Li L, Cabeceiras PK, Mahdavi M, Gutschner T, Genovese G, Wang G, Fang Z, Tepper JM, Stemke-Hale K, Tsai KY, Davies MA, Mills GB, Chin L.

Cancer Res. 2014 Sep 1;74(17):4845-4852. doi: 10.1158/0008-5472.CAN-14-1232-T. Epub 2014 Jul 23.

3.

Reversing paclitaxel resistance in ovarian cancer cells via inhibition of the ABCB1 expressing side population.

Eyre R, Harvey I, Stemke-Hale K, Lennard TW, Tyson-Capper A, Meeson AP.

Tumour Biol. 2014 Oct;35(10):9879-92. doi: 10.1007/s13277-014-2277-2. Epub 2014 Jul 4.

PMID:
24993095
4.

A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation.

Wiegand KC, Hennessy BT, Leung S, Wang Y, Ju Z, McGahren M, Kalloger SE, Finlayson S, Stemke-Hale K, Lu Y, Zhang F, Anglesio MS, Gilks B, Mills GB, Huntsman DG, Carey MS.

BMC Cancer. 2014 Feb 22;14:120. doi: 10.1186/1471-2407-14-120.

5.

Dielectrophoresis has broad applicability to marker-free isolation of tumor cells from blood by microfluidic systems.

Shim S, Stemke-Hale K, Noshari J, Becker FF, Gascoyne PR.

Biomicrofluidics. 2013 Jan 16;7(1):11808. doi: 10.1063/1.4774307. eCollection 2013.

6.

Antibody-independent isolation of circulating tumor cells by continuous-flow dielectrophoresis.

Shim S, Stemke-Hale K, Tsimberidou AM, Noshari J, Anderson TE, Gascoyne PR.

Biomicrofluidics. 2013 Jan 16;7(1):11807. doi: 10.1063/1.4774304. eCollection 2013.

7.

Inferring tumour purity and stromal and immune cell admixture from expression data.

Yoshihara K, Shahmoradgoli M, Martínez E, Vegesna R, Kim H, Torres-Garcia W, Treviño V, Shen H, Laird PW, Levine DA, Carter SL, Getz G, Stemke-Hale K, Mills GB, Verhaak RG.

Nat Commun. 2013;4:2612. doi: 10.1038/ncomms3612.

8.

Gene expression profiling of ampullary carcinomas classifies ampullary carcinomas into biliary-like and intestinal-like subtypes that are prognostic of outcome.

Overman MJ, Zhang J, Kopetz S, Davies M, Jiang ZQ, Stemke-Hale K, Rümmele P, Pilarsky C, Grützmann R, Hamilton S, Hwang R, Abbruzzese JL, Varadhachary G, Broom B, Wang H.

PLoS One. 2013 Jun 11;8(6):e65144. doi: 10.1371/journal.pone.0065144. Print 2013. Erratum in: PLoS One. 2013;8(7). doi:10.1371/annotation/6afdd046-e1a7-4421-b7ec-0c9492ce2544. Zhi-Qin, Jiang [corrected to Jiang, Zhi-Qin].

9.

Frequency of mutations and polymorphisms in borderline ovarian tumors of known cancer genes.

Stemke-Hale K, Shipman K, Kitsou-Mylona I, de Castro DG, Hird V, Brown R, Flanagan J, Gabra H, Mills GB, Agarwal R, El-Bahrawy M.

Mod Pathol. 2013 Apr;26(4):544-52. doi: 10.1038/modpathol.2012.194. Epub 2012 Nov 23.

10.

Correlations between the dielectric properties and exterior morphology of cells revealed by dielectrophoretic field-flow fractionation.

Gascoyne PR, Shim S, Noshari J, Becker FF, Stemke-Hale K.

Electrophoresis. 2013 Apr;34(7):1042-50. doi: 10.1002/elps.201200496.

11.

Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer.

Liang H, Cheung LW, Li J, Ju Z, Yu S, Stemke-Hale K, Dogruluk T, Lu Y, Liu X, Gu C, Guo W, Scherer SE, Carter H, Westin SN, Dyer MD, Verhaak RG, Zhang F, Karchin R, Liu CG, Lu KH, Broaddus RR, Scott KL, Hennessy BT, Mills GB.

Genome Res. 2012 Nov;22(11):2120-9. doi: 10.1101/gr.137596.112. Epub 2012 Oct 1.

12.

A landscape of driver mutations in melanoma.

Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, Nickerson E, Auclair D, Li L, Place C, Dicara D, Ramos AH, Lawrence MS, Cibulskis K, Sivachenko A, Voet D, Saksena G, Stransky N, Onofrio RC, Winckler W, Ardlie K, Wagle N, Wargo J, Chong K, Morton DL, Stemke-Hale K, Chen G, Noble M, Meyerson M, Ladbury JE, Davies MA, Gershenwald JE, Wagner SN, Hoon DS, Schadendorf D, Lander ES, Gabriel SB, Getz G, Garraway LA, Chin L.

Cell. 2012 Jul 20;150(2):251-63. doi: 10.1016/j.cell.2012.06.024.

13.

Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance.

Balko JM, Cook RS, Vaught DB, Kuba MG, Miller TW, Bhola NE, Sanders ME, Granja-Ingram NM, Smith JJ, Meszoely IM, Salter J, Dowsett M, Stemke-Hale K, González-Angulo AM, Mills GB, Pinto JA, Gómez HL, Arteaga CL.

Nat Med. 2012 Jul;18(7):1052-9. doi: 10.1038/nm.2795.

14.

Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers.

Santarpia L, Qi Y, Stemke-Hale K, Wang B, Young EJ, Booser DJ, Holmes FA, O'Shaughnessy J, Hellerstedt B, Pippen J, Vidaurre T, Gomez H, Valero V, Hortobagyi GN, Symmans WF, Bottai G, Di Leo A, Gonzalez-Angulo AM, Pusztai L.

Breast Cancer Res Treat. 2012 Jul;134(1):333-43. doi: 10.1007/s10549-012-2035-3. Epub 2012 Apr 27.

15.

Breast cancer, side population cells and ABCG2 expression.

Britton KM, Eyre R, Harvey IJ, Stemke-Hale K, Browell D, Lennard TW, Meeson AP.

Cancer Lett. 2012 Oct 1;323(1):97-105. doi: 10.1016/j.canlet.2012.03.041. Epub 2012 Apr 17.

16.

Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.

Fu S, Hennessy BT, Ng CS, Ju Z, Coombes KR, Wolf JK, Sood AK, Levenback CF, Coleman RL, Kavanagh JJ, Gershenson DM, Markman M, Dice K, Howard A, Li J, Li Y, Stemke-Hale K, Dyer M, Atkinson E, Jackson E, Kundra V, Kurzrock R, Bast RC Jr, Mills GB.

Gynecol Oncol. 2012 Jul;126(1):47-53. doi: 10.1016/j.ygyno.2012.04.006. Epub 2012 Apr 6.

17.

Systematic analysis of genotype-specific drug responses in cancer.

Kim N, He N, Kim C, Zhang F, Lu Y, Yu Q, Stemke-Hale K, Greshock J, Wooster R, Yoon S, Mills GB.

Int J Cancer. 2012 Nov 15;131(10):2456-64. doi: 10.1002/ijc.27529. Epub 2012 Mar 29.

18.

Detection algorithm for the validation of human cell lines.

Eltonsy N, Gabisi V, Li X, Russe KB, Mills GB, Stemke-Hale K.

Int J Cancer. 2012 Sep 15;131(6):E1024-30. doi: 10.1002/ijc.27533. Epub 2012 Apr 12.

19.

Interactions between tumor cells and microenvironment in breast cancer: a new opportunity for targeted therapy.

Mitra S, Stemke-Hale K, Mills GB, Claerhout S.

Cancer Sci. 2012 Mar;103(3):400-7. doi: 10.1111/j.1349-7006.2011.02183.x. Epub 2012 Jan 30. Review.

20.

Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma.

Joseph RW, Sullivan RJ, Harrell R, Stemke-Hale K, Panka D, Manoukian G, Percy A, Bassett RL, Ng CS, Radvanyi L, Hwu P, Atkins MB, Davies MA.

J Immunother. 2012 Jan;35(1):66-72. doi: 10.1097/CJI.0b013e3182372636.

21.

High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.

Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB.

Cancer Discov. 2011 Jul;1(2):170-85. doi: 10.1158/2159-8290.CD-11-0039. Epub 2011 Jun 7. Erratum in: Cancer Discov. 2012 Aug;2(8):750-1.

22.

Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma.

Prickett TD, Wei X, Cardenas-Navia I, Teer JK, Lin JC, Walia V, Gartner J, Jiang J, Cherukuri PF, Molinolo A, Davies MA, Gershenwald JE, Stemke-Hale K, Rosenberg SA, Margulies EH, Samuels Y.

Nat Genet. 2011 Sep 25;43(11):1119-26. doi: 10.1038/ng.950.

23.

ZNF668 functions as a tumor suppressor by regulating p53 stability and function in breast cancer.

Hu R, Peng G, Dai H, Breuer EK, Stemke-Hale K, Li K, Gonzalez-Angulo AM, Mills GB, Lin SY.

Cancer Res. 2011 Oct 15;71(20):6524-34. doi: 10.1158/0008-5472.CAN-11-0853. Epub 2011 Aug 18.

24.

Exome sequencing identifies GRIN2A as frequently mutated in melanoma.

Wei X, Walia V, Lin JC, Teer JK, Prickett TD, Gartner J, Davis S; NISC Comparative Sequencing Program, Stemke-Hale K, Davies MA, Gershenwald JE, Robinson W, Robinson S, Rosenberg SA, Samuels Y.

Nat Genet. 2011 May;43(5):442-6. doi: 10.1038/ng.810. Epub 2011 Apr 15.

25.

PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer.

Gonzalez-Angulo AM, Ferrer-Lozano J, Stemke-Hale K, Sahin A, Liu S, Barrera JA, Burgues O, Lluch AM, Chen H, Hortobagyi GN, Mills GB, Meric-Bernstam F.

Mol Cancer Ther. 2011 Jun;10(6):1093-101. doi: 10.1158/1535-7163.MCT-10-1089. Epub 2011 Apr 13.

26.

Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer.

Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, Lanchbury JS, Stemke-Hale K, Hennessy BT, Arun BK, Hortobagyi GN, Do KA, Mills GB, Meric-Bernstam F.

Clin Cancer Res. 2011 Mar 1;17(5):1082-9. doi: 10.1158/1078-0432.CCR-10-2560. Epub 2011 Jan 13.

27.

Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation.

Liang K, Esteva FJ, Albarracin C, Stemke-Hale K, Lu Y, Bianchini G, Yang CY, Li Y, Li X, Chen CT, Mills GB, Hortobagyi GN, Mendelsohn J, Hung MC, Fan Z.

Cancer Cell. 2010 Nov 16;18(5):423-35. doi: 10.1016/j.ccr.2010.10.025.

28.

Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma.

Davies MA, Stemke-Hale K, Lin E, Tellez C, Deng W, Gopal YN, Woodman SE, Calderone TC, Ju Z, Lazar AJ, Prieto VG, Aldape K, Mills GB, Gershenwald JE.

Clin Cancer Res. 2009 Dec 15;15(24):7538-7546.

29.

Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates.

Woodman SE, Trent JC, Stemke-Hale K, Lazar AJ, Pricl S, Pavan GM, Fermeglia M, Gopal YN, Yang D, Podoloff DA, Ivan D, Kim KB, Papadopoulos N, Hwu P, Mills GB, Davies MA.

Mol Cancer Ther. 2009 Aug;8(8):2079-85. doi: 10.1158/1535-7163.MCT-09-0459. Epub 2009 Aug 11.

30.

AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer.

Vasudevan KM, Barbie DA, Davies MA, Rabinovsky R, McNear CJ, Kim JJ, Hennessy BT, Tseng H, Pochanard P, Kim SY, Dunn IF, Schinzel AC, Sandy P, Hoersch S, Sheng Q, Gupta PB, Boehm JS, Reiling JH, Silver S, Lu Y, Stemke-Hale K, Dutta B, Joy C, Sahin AA, Gonzalez-Angulo AM, Lluch A, Rameh LE, Jacks T, Root DE, Lander ES, Mills GB, Hahn WC, Sellers WR, Garraway LA.

Cancer Cell. 2009 Jul 7;16(1):21-32. doi: 10.1016/j.ccr.2009.04.012.

31.

Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer.

Agarwal R, Gonzalez-Angulo AM, Myhre S, Carey M, Lee JS, Overgaard J, Alsner J, Stemke-Hale K, Lluch A, Neve RM, Kuo WL, Sorlie T, Sahin A, Valero V, Keyomarsi K, Gray JW, Borresen-Dale AL, Mills GB, Hennessy BT.

Clin Cancer Res. 2009 Jun 1;15(11):3654-62. doi: 10.1158/1078-0432.CCR-08-3293. Epub 2009 May 26.

32.

Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics.

Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, Gilcrease MZ, Krishnamurthy S, Lee JS, Fridlyand J, Sahin A, Agarwal R, Joy C, Liu W, Stivers D, Baggerly K, Carey M, Lluch A, Monteagudo C, He X, Weigman V, Fan C, Palazzo J, Hortobagyi GN, Nolden LK, Wang NJ, Valero V, Gray JW, Perou CM, Mills GB.

Cancer Res. 2009 May 15;69(10):4116-24. doi: 10.1158/0008-5472.CAN-08-3441. Epub 2009 May 12.

33.

Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer.

Gonzalez-Angulo AM, Stemke-Hale K, Palla SL, Carey M, Agarwal R, Meric-Berstam F, Traina TA, Hudis C, Hortobagyi GN, Gerald WL, Mills GB, Hennessy BT.

Clin Cancer Res. 2009 Apr 1;15(7):2472-8. doi: 10.1158/1078-0432.CCR-08-1763. Epub 2009 Mar 10.

34.

A novel AKT3 mutation in melanoma tumours and cell lines.

Davies MA, Stemke-Hale K, Tellez C, Calderone TL, Deng W, Prieto VG, Lazar AJ, Gershenwald JE, Mills GB.

Br J Cancer. 2008 Oct 21;99(8):1265-8. doi: 10.1038/sj.bjc.6604637. Epub 2008 Sep 23.

35.

An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.

Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y, Sahin A, Symmans WF, Pusztai L, Nolden LK, Horlings H, Berns K, Hung MC, van de Vijver MJ, Valero V, Gray JW, Bernards R, Mills GB, Hennessy BT.

Cancer Res. 2008 Aug 1;68(15):6084-91. doi: 10.1158/0008-5472.CAN-07-6854.

36.

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, Beijersbergen RL, Mills GB, van de Vijver MJ, Bernards R.

Cancer Cell. 2007 Oct;12(4):395-402.

37.

Molecular screening for breast cancer prevention, early detection, and treatment planning: combining biomarkers from DNA, RNA, and protein.

Stemke-Hale K, Hennessy B, Mills GB, Mitra R.

Curr Oncol Rep. 2006 Nov;8(6):484-91. Review.

PMID:
17040626
38.

Expression library immunization: a road map for discovery of vaccines against infectious diseases.

Talaat AM, Stemke-Hale K.

Infect Immun. 2005 Nov;73(11):7089-98. Review. No abstract available.

39.

Screening the whole genome of a pathogen in vivo for individual protective antigens.

Stemke-Hale K, Kaltenboeck B, DeGraves FJ, Sykes KF, Huang J, Bu CH, Johnston SA.

Vaccine. 2005 Apr 27;23(23):3016-25.

PMID:
15811648
40.

A library-selected, Langerhans cell-targeting peptide enhances an immune response.

McGuire MJ, Sykes KF, Samli KN, Timares L, Barry MA, Stemke-Hale K, Tagliaferri F, Logan M, Jansa K, Takashima A, Brown KC, Johnston SA.

DNA Cell Biol. 2004 Nov;23(11):742-52.

PMID:
15585132
41.

Applications of, and future challenges for, genetic vaccines.

Johnston SA, Qu BX, McGuire M, Stemke-Hale K, Sykes K.

Dev Biol (Basel). 2000;104:3-8.

PMID:
11713821
42.

Direct association between the yeast Rad51 and Rad54 recombination proteins.

Jiang H, Xie Y, Houston P, Stemke-Hale K, Mortensen UH, Rothstein R, Kodadek T.

J Biol Chem. 1996 Dec 27;271(52):33181-6.

43.

The phage T4 uvs Y recombination protein stabilizes presynaptic filaments.

Kodadek T, Gan DC, Stemke-Hale K.

J Biol Chem. 1989 Oct 5;264(28):16451-7.

Supplemental Content

Loading ...
Support Center